Dose-response of Albuterol in Asthmatics

• Status: Completed
• Trial end date: 1994-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to determine the lung function response after increasing doses of albuterol (a bronchodilator) in children and adults with asthma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nemours Children's Clinic
• Treatments: Albuterol

Criteria

Eligibility Criteria:

• Well-defined history of physician diagnosed asthma

• Any ethnic background

• 8 to 65 years old

• Baseline pre-bronchodilator FEV1 of 40% to 80% predicted for age, height, and gender

• No oral corticosteroid use, emergency room visits, or hospitalizations within the previous 3 months

• Nonsmokers or less than a 5 pack-year history with no smoking in the previous year

• Normal physical exam and no confounding diseases were selected

• Able to withhold inhaled short-acting b2-agonists or inhaled anticholinergic drugs for 8 hours, oral antihistamines for 5 days, theophylline for 24 hours, and cromolyn, nedocromil, and inhaled corticosteroids for 2 hours prior to the study.